Printer Friendly

BIOGEN ANNOUNCES HIRULOG PATENT ALLOWANCE AND PHASE III TRIAL IN ANGIOPLASTY

 SAN FRANCISCO, Jan. 12 /PRNewswire/ -- Biogen Inc. (NASDAQ-NMS: BGEN) today announced that it has received a notice of patent allowance for Hirulog(tm), its lead proprietary cardiovascular compound, and disclosed plans to begin a Phase III clinical trial for Hirulog in angioplasty. Speaking at the 11th annual Hambrecht & Quist Life Sciences Conference, James L. Vincent, Biogen's chairman and chief executive officer, also announced preliminary 1992 financial results. Revenues are expected to exceed $135 million, with earnings per share to exceed $1.10 compared to revenues of $70 million and earnings per share of 15 cents in 1991.
 "The company is quite pleased by the recent news from the U.S. Patent Office, as a strong patent is critical to successful drug development," Vincent said. "This news, along with the start of the second Phase III trial, underscores our enthusiasm for the compound."
 "Biogen had an outstanding year financially in 1992, largely as a result of the unprecedented increase in sales by our licensees of hepatitis B vaccines and alpha interferon," Vincent said. "During the same period, our research and development expense growth was almost equally dramatic -- up more than 35 percent -- directly due to our aggressive clinical trials program. We anticipate some variability in the level of revenues and earnings over the next few years, rather than consistent earnings growth, until Biogen is selling its own proprietary products."
 Biogen, Inc., headquartered in Cambridge, Mass., is a biopharmaceutical company principally engaged in developing and manufacturing drugs for human healthcare through genetic engineering. The company's revenues are generated from the worldwide sales by licensees of five products, including alpha interferon and hepatitis B vaccines and diagnostic products. Biogen is focused primarily on developing and testing products for the treatment of cardiovascular disease, inflammatory diseases, AIDS, certain cancers and viruses.
 -0- 1/12/93
 /CONTACT: Kathryn R. Bloom, director of communications, 617-252-9851 or Amy S. Hedison, director, investor relations, 617-252- 9873, both of Biogen/
 (BGEN)


CO: Biogen, Inc. ST: Massachusetts IN: MTC SU:

DD -- NE016 -- 4131 01/12/93 15:00 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 12, 1993
Words:339
Previous Article:TED NUGENT ARRESTED
Next Article:CHEVRON U.S.A. PRODUCTS COMPANY PURCHASES BANCTEC IMAGEFIRST DOCUMENT PROCESSING SYSTEM
Topics:


Related Articles
CV Therapeutics Receives $6.5 Million Milestone From Biogen.
Positive Results With Biogen's A1 Adenosine Receptor Antagonist in Congestive Heart Failure Presented at American College of Cardiology.
Biogen Reaffirms First Quarter and Full Year 2001 Guidance With Update on Royalty Revenue Status.
Biogen Completes Phase III Trials of AMEVIVE(TM), Will File Applications for Worldwide Marketing Approvals.
BIOGEN COMPLETES PHASE III TRIALS OF AMEVIVE.
BIOGEN COMPLETES INTERNATIONAL REGISTRATIONAL FILING FOR AMEVIVE (ALEFACEPT).
Biogen Completes International Registrational Filing For AMEVIVE(TM) (ALEFACEPT).
Biogen Announces Third Quarter 2001 Earnings Per Share Increased to $0.46 From $0.44 in 2000.
BIOGEN ANNOUNCES THIRD QUARTER 2001 EARNINGS PER SHARE INCREASED TO USD 0.46 FROM USD 0.44 IN 2000.
Biogen Cites Goal of Surpassing $2 Billion in Revenues in 2005.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters